Investors

  • 메인

  • Investors

Overview

INGENIA Therapeutics is pioneering a new paradigm in vascular normalization
and remains committed to enhancing corporate value through sustainable
growth and responsible management.

Stock Information

  • INGENIA Therapeutics 950260
  • Current Price 24,200
    • Price Change 750 (+3.20%)
    • Trading Value 79,268,095,725
    • Trading Volume(Shares) 3,339,114

As of --:-- (EST), --- --, ----

Open 23,150
Upper Limit 30,450
Lower Limit 16,450

Shareholding Structure

Category Number of DRs Ownership(%)
Existing Investors 34,030,767 68.8
Major Shareholder & Related Parties 10,158,344 20.6
Public Shareholders 5,255,496 10.6
Total 49,444,607 100.0

* Shareholding structure as of June 30, 2026

Financial Information

(Unit: USD)
CategoryFY2025FY2024FY2023
Sales-2,588,4004,313,696
Operating Profit(23,338,334)(7,721,414)(1,683,423)
Profit Before Income Tax(20,115,594)22,105,213(997,117)
Net Income(18,596,626)15,731,843(1,004,860)
Total Comprehensive Income(18,584,333)15,728,338(1,004,860)

 ​ 

(Unit: USD)
CategoryFY2025FY2024FY2023
Current Assets16,071,81027,253,0863,958,435
Non-current Assets4,328,93010,649,7142,867,516
Total Assets20,400,74037,902,8006,825,951
Current Liabilities6,068,0125,873,5582,810,539
Non-current Liabilities666,4981,215,078-
Total Liabilities6,734,5107,088,6362,810,539
Total Equity13,666,23030,814,1644,015,412

 ​ 

(Unit: USD)
CategoryFY2025FY2024FY2023
Operating Activities(21,787,017)(13,453,734)(1,542,696)
Investing Activities

24,977,524

1,901,456

(1,595,464)
Financing Activities32,17110,416,4831,247,374
Net Increase in Cash3,217,661(1,136,236)(1,890,786)
Beginning Cash Balance818,0651,954,3013,845,087
FX Effect(5,017)(441)-
Ending Cash Balance4,035,726818,0651,954,301